Nurix Therapeuticsinc Stock Total Debt
| NRIX Stock | USD 16.74 0.47 2.73% |
Nurix TherapeuticsInc fundamentals help investors to digest information that contributes to Nurix TherapeuticsInc's financial success or failures. It also enables traders to predict the movement of Nurix Stock. The fundamental analysis module provides a way to measure Nurix TherapeuticsInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nurix TherapeuticsInc stock.
Total Debt To Capitalization is likely to rise to 0.13 in 2024. Nurix | Total Debt |
Nurix TherapeuticsInc Company Total Debt Analysis
Nurix TherapeuticsInc's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Nurix TherapeuticsInc Total Debt | 30.61 M |
Most of Nurix TherapeuticsInc's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nurix TherapeuticsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nurix Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Nurix TherapeuticsInc is extremely important. It helps to project a fair market value of Nurix Stock properly, considering its historical fundamentals such as Total Debt. Since Nurix TherapeuticsInc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nurix TherapeuticsInc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nurix TherapeuticsInc's interrelated accounts and indicators.
Click cells to compare fundamentals
Nurix Total Debt Historical Pattern
Today, most investors in Nurix TherapeuticsInc Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nurix TherapeuticsInc's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Nurix TherapeuticsInc total debt as a starting point in their analysis.
Nurix TherapeuticsInc Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Nurix Net Debt
Based on the latest financial disclosure, Nurix TherapeuticsInc has a Total Debt of 30.61 M. This is 98.89% lower than that of the Biotechnology sector and 90.57% lower than that of the Health Care industry. The total debt for all United States stocks is 99.42% higher than that of the company.
Nurix Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nurix TherapeuticsInc's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nurix TherapeuticsInc could also be used in its relative valuation, which is a method of valuing Nurix TherapeuticsInc by comparing valuation metrics of similar companies.Nurix TherapeuticsInc is currently under evaluation in total debt category among related companies.
Nurix TherapeuticsInc Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nurix TherapeuticsInc from analyzing Nurix TherapeuticsInc's financial statements. These drivers represent accounts that assess Nurix TherapeuticsInc's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nurix TherapeuticsInc's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 668.0M | 1.2B | 602.3M | 338.0M | 304.2M | 518.5M | |
| Enterprise Value | 548.6M | 1.2B | 549.7M | 314.0M | 282.6M | 475.4M |
Nurix TherapeuticsInc Institutional Holders
Institutional Holdings refers to the ownership stake in Nurix TherapeuticsInc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nurix TherapeuticsInc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nurix TherapeuticsInc's value.| Shares | Dimensional Fund Advisors, Inc. | 2023-12-31 | 1 M | State Street Corporation | 2023-12-31 | 921.3 K | Candriam Luxembourg S.c.a. | 2023-12-31 | 918.1 K | Pictet Asset Manangement Sa | 2023-12-31 | 773.6 K | Tcg Crossover Management, Llc | 2023-12-31 | 717.7 K | Affinity Asset Advisors, Llc | 2023-12-31 | 690.1 K | Charles Schwab Investment Management Inc | 2023-12-31 | 622.3 K | Goldman Sachs Group Inc | 2023-12-31 | 563.8 K | Nuveen Asset Management, Llc | 2023-12-31 | 533.9 K | Blackrock Inc | 2023-12-31 | 4.6 M | Baker Bros Advisors Lp | 2023-12-31 | 3.9 M |
Nurix Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.79) % | ||||
| Operating Margin | (2.73) % | ||||
| Current Valuation | 607.95 M | ||||
| Shares Outstanding | 49.15 M | ||||
| Shares Owned By Insiders | 2.60 % | ||||
| Shares Owned By Institutions | 97.95 % | ||||
| Number Of Shares Shorted | 6.97 M | ||||
| Price To Book | 4.88 X | ||||
| Price To Sales | 10.17 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (145.87 M) | ||||
| EBITDA | (141.41 M) | ||||
| Net Income | (143.95 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 30.61 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | (81.36 M) | ||||
| Short Ratio | 7.00 X | ||||
| Earnings Per Share | (2.66) X | ||||
| Target Price | 23.4 | ||||
| Number Of Employees | 284 | ||||
| Beta | 2.06 | ||||
| Market Capitalization | 822.78 M | ||||
| Total Asset | 364.54 M | ||||
| Retained Earnings | (545.2 M) | ||||
| Working Capital | 208.54 M | ||||
| Net Asset | 364.54 M |
About Nurix TherapeuticsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nurix TherapeuticsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix TherapeuticsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix TherapeuticsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Nurix TherapeuticsInc Piotroski F Score and Nurix TherapeuticsInc Altman Z Score analysis. For more information on how to buy Nurix Stock please use our How to Invest in Nurix TherapeuticsInc guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Nurix Stock analysis
When running Nurix TherapeuticsInc's price analysis, check to measure Nurix TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix TherapeuticsInc is operating at the current time. Most of Nurix TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Nurix TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix TherapeuticsInc's price. Additionally, you may evaluate how the addition of Nurix TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Nurix TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix TherapeuticsInc. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.483 | Quarterly Revenue Growth 0.307 | Return On Assets (0.29) | Return On Equity (0.65) |
The market value of Nurix TherapeuticsInc is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Nurix TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix TherapeuticsInc's market value can be influenced by many factors that don't directly affect Nurix TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nurix TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nurix TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.